Cat. #161945
SW48-PLCG1
Cat. #: 161945
Availability: 8-10 weeks
Organism: Human
Tissue: Epithelial
Disease: Cancer
Model: Over-expression
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Marta Martins
Institute: Instituto de Medicina Molecular João Lobo Antunes
Primary Citation: Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SW48-PLCG1
- Cancer: Digestive / Gastrointestinal cancer
- Research fields: Cancer
- Parental cell: SW480
- Organism: Human
- Gender: Male
- Tissue: Epithelial
- Disease: Cancer
- Growth properties: A subcultivation ratio of 1:4 to 1:6 is recommended, 1 to 2 times per week.
- Model: Over-expression
- Crispr: No
- Description: For stable PLCG1 overexpression (SW48-PLCG1), SW48 cells were infected with PLCG1 lentiviral activation particles (Santa Cruz Biotechnology). Selection of stable clones started 2 days after infection with a mix of 2 ?g/mL Puromycin, 50 mg/mL Hygromicyn B, and 10 mg/mL Blasticidin.
- Biosafety level: 1
- Recommended controls: shRNA scrambled control
Target Details
- Target: PLCG1
- Target background: Phospholipase C gamma 1 is a ubiquitously expressed enzyme that catalyses the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction plays an important role in the intracellular transduction of receptor- and non-receptor- mediated tyrosine kinase activators, which has major implications in several cellular processes such as proliferation, migration, and angiogenesis. More recently, PLC?1 was shown involved in anti-EGFR therapy re...
Handling
- Format: Frozen
- Growth medium: DMEM with 10% FBS, 5% CO2
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
References
- Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600
